Actinium Pharmaceuticals 8K/A Entry into a Material Definitive Agreement | ATNM 4 Jan 13

Filing exhibits

8-K/A Current report
10.1 Registration Rights Agreement, by and Among Actinium Pharmaceuticals, Inc., General Atlantic Investments Limited, and Certain Stockholders, Dated June 30, 2000 (Incorporated by Reference to Exhibit 10.1 to Form 8-K Filed on January 2, 2013).
10.2 Amendment No. 1 to June 30, 2000 Registration Rights Agreement, Dated September 29, 2011.
10.3 First Amended and Restated Stockholders Agreement, by and Among Actinium Pharmaceuticals, Inc., Actinium Holdings Limited, N.V. Organon, and the Stockholders Listed Therein, Dated October 5, 2011.
10.4 Second Amended and Restated Investor Rights Agreement, by and Among Actinium Pharmaceuticals, Inc., Actinium Holdings Limited, and the Investors Listed Therein, Dated October 5, 2011.
10.5 Placement Agent Engagement Agreement, by and Between Laidlaw & Company (Uk) LTD. and Actinium Pharmaceuticals, Inc., Dated August 7, 2012.
10.8 Employment Agreement, Dated January 2, 2006, Between Actinium Pharmaceuticals, Inc. and Dragan Cicic
10.9 License, Development and Commercialization Agreement Between Sloan-kettering Institute of Cancer Research, and Actinium Pharmaceuticals, Inc., Dated February 11, 2002; As Amended by the First Amendment Dated August 7, 2006
10.10 Phase I/ii Study on the Safety and Efficiency of 225ACAC-HUM195 In Patients with Advanced Myeloid Malignancies with Millennix Oncology, Averion Project, Dated December 6, 2006.
10.11 Product Development and Patent License Agreement, Dated February 27, 2003, by and Between Abbott Biotherapeutics and Actinium Pharmaceuticals, Inc.
10.12 Clinical Trial Agreement, Dated July 19, 2012, by and Between Fred Hutchinson Cancer Center and Actinium Pharmaceuticals, Inc.
10.13 Employment Letter Between Jack V. Talley and Actinium Pharmaceuticals, Inc., Effective August 15, 2012.
10.14 Employment Letter Between Enza Guagenti and Actinium Pharmaceuticals, Inc., Effective August 15, 2012.
10.15 Clinical Trial Agreement, Dated January 18, 2001, Between Actinium Pharmaceuticals, Inc. and Memorial Sloan Kettering Cancer Center for the Purpose of Conducting a Clinical Trial Entitled ?Phase I/ii Trial of 213BI-M195 and Cytarabine for Acute Myeloid Le
10.16 Clinical Trial Agreement with the Trustees of the University of Pennsylvania, Dated November 8, 2012.
10.17 Clinical Trial Agreement, Dated March 27, 2012, with Memorial Sloan-kettering Cancer Center.
10.18 Clinical Trial Agreement, Dated September 22, 2012, with Johns Hopkins University, Dated September 24, 2012.
10.19 License Agreement, Dated June 14, 2012, for BC8 Antibody with Fred Hutchinson Cancer Research Center.
10.20 2012 Unit Investor Rights Agreement, Dated December 19, 2012, by and Among Actinium Pharmaceuticals, Inc., the Persons Identified on Exhibit a Attached Thereto Hereto, and the Placement Agent (Defined Below).
10.21 Project Agreement, Dated September 30, 2011, Between Actinium Pharmaceuticals, Inc. and Aptiv Solutions, Inc.
10.22 Proposal, Dated March 30, 2007, with Isotherapeutics Group, LLC.
10.23 Clinical Trial Agreement with the University of Texas M.D. Anderson Cancer, Dated March 1, 2012.
10.24 Amendment No. 1 to Research Agreement, Dated November 7, 2012, Between Actinium Pharmaceuticals, Inc. and the University of Texas M.D. Anderson Cancer.
10.25 Letter Agreement, Dated June 19, 2011, Between Actinium Pharmaceuticals, Inc. and Sloan-kettering Institute for Cancer Research.
10.26 Letter Agreement, Dated April 9, 2010, Between Actinium Pharmaceuticals, Inc. and Sloan-kettering Institute for Cancer Research.
10.27 Letter Agreement, Dated July __, 2010, Between Actinium Pharmaceuticals, Inc. and Actinium Holdings Limited (Waiver of Anti-dilution Rights).
10.28 Clinical Trial Agreement, Dated April 12, 2006, with Sloan-kettering Institute for Cancer Research and Memorial Hospital for Cancer and Allied Diseases.
10.29 Letter Agreement, Dated __, 2011, Between Actinium Pharmaceuticals, Inc. and Actinium Holdings Limited (Waiver of Registration Rights).
99.3 EX-99.3

Actinium Pharmaceuticals (ATNM) 8-K/AEntry into a Material Definitive Agreement